Market closedNon-fractional
Pyxis Oncology/PYXS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Pyxis Oncology
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Ticker
PYXS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
51
Website
www.pyxisoncology.com
Pyxis Oncology Metrics
BasicAdvanced
$227M
Market cap
-
P/E ratio
-$1.32
EPS
1.33
Beta
-
Dividend rate
Price and volume
Market cap
$227M
Beta
1.33
Financial strength
Current ratio
12.19
Quick ratio
11.67
Long term debt to equity
10.729
Total debt to equity
11.283
Management effectiveness
Return on assets (TTM)
-19.95%
Return on equity (TTM)
-34.37%
Valuation
Price to revenue (TTM)
10.465
Price to book
1.23
Price to tangible book (TTM)
1.41
Price to free cash flow (TTM)
-2.517
Growth
Earnings per share change (TTM)
-59.01%
3-year earnings per share growth (CAGR)
-68.32%
What the Analysts think about Pyxis Oncology
Analyst Ratings
Majority rating from 7 analysts.
Pyxis Oncology Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$16M
∞%
Net income
-$3.2M
-79.35%
Profit margin
-19.87%
-∞%
Pyxis Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.41
-$0.56
-$0.33
-$0.06
-
Expected
-$0.65
-$0.51
-$0.48
-$0.24
-$0.32
Surprise
-36.68%
10.53%
-30.53%
-75.21%
-
Pyxis Oncology News
AllArticlesVideos
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
GlobeNewsWire·2 months ago
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pyxis Oncology stock?
Pyxis Oncology (PYXS) has a market cap of $227M as of July 27, 2024.
What is the P/E ratio for Pyxis Oncology stock?
The price to earnings (P/E) ratio for Pyxis Oncology (PYXS) stock is 0 as of July 27, 2024.
Does Pyxis Oncology stock pay dividends?
No, Pyxis Oncology (PYXS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Pyxis Oncology dividend payment date?
Pyxis Oncology (PYXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Pyxis Oncology?
Pyxis Oncology (PYXS) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Pyxis Oncology stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.